oral semaglutide intermittent fasting
7 Shocking Ways FDA Takedown Obliterates Obesity Treatment
The FDA’s recent decision to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk-compounding list cuts off cheaper pharmacy-made versions, limits clinical flexibility, and jeopardizes emerging combination strategies like semaglutide paired with intermittent fasting. In my practice I see patients scramble for approved prescriptions while the market narrows, and